Faruqi & Faruqi Urges Unicycive Shareholders to Act By October 14, 2025, Regarding Class Action Lawsuit

Important Update for Unicycive Investors

Faruqi & Faruqi, LLP, a prominent name in securities law, is currently investigating possible claims against Unicycive Therapeutics, Inc., a company facing serious challenges with its FDA submissions. Investors who have experienced losses exceeding $50,000 between March 29, 2024, and June 27, 2025, are particularly encouraged to engage with the firm for potential legal actions.

The firm has highlighted that the looming deadline for becoming a lead plaintiff in a federal securities class action lawsuit is October 14, 2025. This could be a pivotal opportunity for investors affected by Unicycive's operational issues to seek redress.

What Happened?

On June 10, 2025, Unicycive disclosed significant deficiencies found by the FDA regarding its compliance with manufacturing practices. This revelation led to a sharp decline in the company's stock price, plummeting nearly 41% in a single day. Furthermore, another FDA communication on June 30, 2025, issued a Complete Response Letter concerning their New Drug Application for OLC, again citing problems with their manufacturing processes. Following this news, another substantial dip of approximately 30% in share value was witnessed.

These developments have raised red flags among investors about the company's disclosures and operational transparency. Allegations are surfacing that Unicycive's executives may have misrepresented the organization's readiness to meet the FDA's stringent requirements. This has caused considerable uncertainty over the legitimacy of their public statements, which could have dire consequences for shareholders.

How to Get Involved

Investors are urged to act swiftly if they believe they qualify as lead plaintiffs. The lead plaintiff is typically the individual or entity with the most substantial financial stake, tasked with directing the litigation effectively while representing the class's interests. The role can potentially maximize recovery outcomes for all involved parties, but it’s also entirely possible for investors to remain anonymous class members, preserving their rights to any settlements without taking on a more active role.

Contact Faruqi & Faruqi: If you have critical information regarding Unicycive’s actions or have faced financial losses due to their alleged misconduct, your insights may be invaluable. The firm is particularly interested in hearing from whistleblowers, former employees, and shareholders alike.

For a deeper understanding of your legal rights or to begin discussions on participating in the class action, contact Faruqi & Faruqi directly at `877-247-4292` or `212-983-9330 Ext. 1310`. Alternatively, you can visit their website for more resources and information on the ongoing Unicycive Therapeutics investigation.

Conclusion

Investors in Unicycive Therapeutics must remain vigilant and proactive during this turbulent time. The October 14, 2025, cutoff is approaching swiftly, and those who have suffered losses should consider their options carefully. Acting now could offer a path toward recovery amid a challenging situation for the company and its shareholders.